Market capitalization | $2.89b |
Enterprise Value | $2.55b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 39.11 |
P/S ratio (TTM) P/S ratio | 44.30 |
P/B ratio (TTM) P/B ratio | 4.03 |
Revenue growth (TTM) Revenue growth | 37.64% |
Revenue (TTM) Revenue | $65.18m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Recursion Pharmaceuticals forecast:
7 Analysts have issued a Recursion Pharmaceuticals forecast:
Sep '24 |
+/-
%
|
||
Revenue | 65 65 |
38%
38%
|
|
Gross Profit | -2.14 -2.14 |
44%
44%
|
|
EBITDA | -365 -365 |
28%
28%
|
EBIT (Operating Income) EBIT | -404 -404 |
30%
30%
|
Net Profit | -378 -378 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Chistopher Gibson |
Founded | 2013 |
Website | www.recursion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.